GlassScriptPhysician profile
Andrew Guidry
NPI 1982961009
$4,005.64
in general payments reported to CMS, 2019-2025
40 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $733 · 2021: $881 · 2022: $385 · 2023: $91.68 · 2024: $61.18 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $813.32 | 2019-2025 | |
| Allergan, INC. | $526.90 | 2019-2021 | |
| Abbvie INC. | $405.15 | 2021-2025 | |
| Pfizer INC. | $178.85 | 2024-2025 | |
| Genzyme Corporation | $162.10 | 2019-2022 | |
| Lundbeck LLC | $160.55 | 2021-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $151.16 | 2022-2025 | Ultomiris |
| Biogen, INC. | $139.49 | 2019-2021 | |
| Amgen INC. | $128.24 | 2021-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $116.76 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $113.77 | 2019-2021 | |
| Ucb, INC. | $111.24 | 2019-2025 | Nayzilam, Rystiggo |
| Neurelis, INC. | $74.69 | 2020-2025 | Valtoco |
| Csl Behring | $65.95 | 2019-2021 | |
| Eisai INC. | $60.60 | 2021-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Guidry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.